Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.38 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.38 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30961080 | 0.93 | CNR2 (0.38) | TLR9TLR8TLR7CNR2 | |
| SCHEMBL29909185 | 0.88 | CNR2 (0.35) | TLR9TLR8TLR7KCNH2CNR2 | |
| SCHEMBL29909090 | 0.86 | CNR2 (0.37) | TLR9TLR8TLR7ACVR1CNR2 | |
| SCHEMBL29909353 | 0.83 | ABCG2 (0.37) | — | |
| SCHEMBL29909708 | 0.83 | ABCG2 (0.41) | — | |
| SCHEMBL29909741 | 0.83 | NPC1 (0.43) | TLR8TLR7MAP3K11 | |
| SCHEMBL29909361 | 0.82 | HSD17B1 (0.39) | — | |
| SCHEMBL29909542 | 0.81 | ABCG2 (0.34) | — | |
| SCHEMBL23578268 | 0.81 | CNR2 (0.39) | NTRK1TLR9TLR8TLR7KCNH2 | |
| SCHEMBL29909687 | 0.80 | ABCG2 (0.37) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | NTRK1 2949/4885TLR9 2369/4885TLR8 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.